Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

290 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fatigue, a major still underestimated issue.
Ripamonti CI, Antonuzzo A, Bossi P, Cavalieri S, Roila F, Fatigoni S. Ripamonti CI, et al. Among authors: cavalieri s. Curr Opin Oncol. 2018 Jul;30(4):219-225. doi: 10.1097/CCO.0000000000000451. Curr Opin Oncol. 2018. PMID: 29877886 Review.
Lenvatinib-induced renal failure: two first-time case reports and review of literature.
Cavalieri S, Cosmai L, Genderini A, Nebuloni M, Tosoni A, Favales F, Pistillo P, Bergamini C, Bossi P, Licitra L, Locati LD, Alfieri S. Cavalieri S, et al. Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):379-385. doi: 10.1080/17425255.2018.1461839. Epub 2018 Apr 13. Expert Opin Drug Metab Toxicol. 2018. PMID: 29617171 Free article. Review.
Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer.
Cavalieri S, Perrone F, Miceli R, Ascierto PA, Locati LD, Bergamini C, Granata R, Alfieri S, Resteghini C, Galbiati D, Busico A, Paielli N, Patuzzo R, Maurichi A, Gallino G, Ruggeri R, Mariani L, Palla M, Licitra L, Bossi P. Cavalieri S, et al. Eur J Cancer. 2018 Jul;97:7-15. doi: 10.1016/j.ejca.2018.04.004. Epub 2018 May 4. Eur J Cancer. 2018. PMID: 29734047 Clinical Trial.
Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting.
Depenni R, Cossu Rocca M, Ferrari D, Azzarello G, Baldessari C, Alù M, Nolé F, Codecà C, Boscolo G, Piccininni M, Cavalieri S, Bossi P. Depenni R, et al. Among authors: cavalieri s. Eur J Cancer. 2019 Jul;115:4-12. doi: 10.1016/j.ejca.2019.03.022. Epub 2019 May 10. Eur J Cancer. 2019. PMID: 31082692
290 results